In This Section

Cardiovascular Consequences of Metabolic Targeting in Obesity

Wednesday April 25, 2018

8:30 am - 11:00 am

Room 16B
Sponsored by the Division for Cardiovascular Pharmacology (CVP)
Co-sponsored by the Division for Pharmacology Education (DPE)
Co-sponsored by the Division for Translational and Clinical Pharmacology (TCP)

Chair :

Amy Arnold
Penn State College of Medicine

Debra Diz
Wake Forest School of Medicine


Obesity is increasing at an alarming rate worldwide. The majority of obese patients have hypertension, which increases risk for cardiovascular disease. While there is a well-established clinical association, there is an unmet need to better understand integrative molecular and hormonal mechanisms underlying cardiovascular and metabolic derangements in obesity. A failure to consider overlap in the pathways regulating these functions has led to adverse cardiovascular effects of several anti-obesity drugs. This symposium will highlight the need to study integrative cardiometabolic mechanisms in obesity, and will describe potential pharmacologic targets with evidence for positive metabolic and cardiovascular effects in this disease.

Adiponectin: An Emerging Adipokine Mediator of Cardiovascular and Metabolic Health
Philipp Scherer - The University of Texas Southwestern Medical Center

Angiotensin-(1-7): A Positive Force for Cardiometabolic Function
Amy Arnold - Penn State College of Medicine

Hypothalamic Inflammation: A Novel Target Linking Energy Imbalance and Hypertension in Obesity
Dongsheng Cai - Albert Einstein College of Medicine

The Endocannabinoid System and Cardiometabolic Risk Factors
Debra Diz - Wake Forest School of Medicine

Disrupted Adiponectin-Connexin43 Signaling Underlies the Exacerbated Myocardial Dysfunction in Diabetic Female Rats
Korin Leffler - East Carolina University, Brody School of Medicine

Angiotensin-(1-7)-Mediated Increases in Energy Expenditure Appear Independent of the Hypothalamic Melanocortin System
Rebecca Fleeman - University of Florida

Intra-Abdominal Lipectomy Reduces Large Arterial Stiffness and Blood Pressure in Metabolic Syndrome
Amanda Soler - New York Medical College

Thank you to our Annual Meeting partners:

Amgen
University of Florida
Wake Forest University
Washington State University College of Pharmacy and Pharmaceutical Sciences
University of Wisconsin Molecular and Cellular Pharmacology Training Program
UT Health San Antonio
University of Minnesota

Emory University Pharmacology

PR & P
University of Michigan Medical School Pharmacology
jpet_banner
molpharm_banner
dmd_banner
pharmrev_banner